Figure 1

Experimental setting. (A) Thirty-two ApoE^−/−-mice and 12 ApoE^−/−/AT1R^−/−-mice were rendered diabetic after injections of streptozotocin. The same quantity of ApoE^−/− and ApoE^−/−/AT1R^−/−-mice received vehicle alone and served as non-diabetic controls. Diabetic and non-diabetic ApoE^−/−-mice were further randomized in groups of 8 animals to receive telmisartan, GW9662, telmisartan and GW9962 or vehicle for 18 weeks. Diabetic and non-diabetic ApoE^−/−/AT1R^−/−-mice were further randomized in groups of 6 animals to receive either GW9662 or vehicle for 18 weeks. (B) After treatment of 18 weeks mice were sacrificed and read-outs were performed.